Abbott Laboratories (ABT) delivered a strong Q2 2026 performance that surprised Wall Street, with the healthcare giant posting a double beat on both top and bottom lines on July 16, 2026. The earnings ...

Abbott (ABT) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Shares ...

Wall Street still prices Abbott like a dividend stalwart, but overlooked moves suggest that framing may be costing investors ...

Abbott Laboratories (NYSE:ABT) delivered strong fiscal Q2 2026 results, beating quarterly estimates and raising its annual ...

Over the past few years, the exciting field of artificial intelligence (AI) has captured much of Wall Street's attention and headlines. And sure enough, some of the leaders in AI have produced ...

Abbott Laboratories is now fairly valued after a 26% decline from its 2021 highs, but I maintain a Hold rating. ABT's Q1/26 saw 7.8% revenue growth, with medical devices leading, but operating income ...

On the hunt for the market's most reliable stocks? Long-term investors would be hard-pressed to do better than Abbott Laboratories , one of health care's premier blue-chippers and a dividend ...

There are few names in healthcare that combine durability, innovation, and income quite like Abbott Laboratories (ABT). Yet ,even the strongest operators hit periods where sentiment softens and ...

Abbott Laboratories is investigating two separate cybersecurity incidents after confirming unauthorized access to internal ...

Abbott Laboratories' business, if not exciting, is resilient and consistent. The company is a leader in multiple markets and has attractive growth avenues. The medical device leader boasts a strong ...